Key positives include a strong cash position with very little debt, giving the company time and flexibility to pursue its clinical programs; a clean, straightforward balance sheet; and a clear, differentiated scientific strategy targeting a well-understood pathway in a high-value rare disease. The dual acute-and-preventive oral approach, backed by encouraging late-stage data for the acute indication, offers a compelling potential product profile. Management appears to be prioritizing R&D spending over non-essential costs, which is appropriate for this stage.

Major risks stem from the lack of revenue and ongoing heavy cash burn, which make the company reliant on successful trials and continued access to capital. Clinical and regulatory outcomes remain uncertain, especially for the preventive tablet and additional indications, and competition from other oral and injectable HAE therapies is already established. The business is heavily concentrated in one primary asset, so any safety, efficacy, or regulatory issues with deucrictibant could significantly impair the company’s prospects.

The forward picture is binary and catalyst-driven. In the near to medium term, trial readouts, regulatory filings, and potential approvals for deucrictibant will largely determine whether Pharvaris can transition from a cash-burning R&D story to a commercial rare-disease company with meaningful revenue and, eventually, profitability. If the data and regulatory path are favorable, the company could carve out a strong position in the evolving HAE market; if not, it may need to rethink its strategy, secure new capital under more challenging conditions, or explore strategic alternatives. Overall, the outlook carries high uncertainty but also material upside potential tied to a small number of pivotal milestones.